论文部分内容阅读
目的 分析乳腺癌病人外周血 T细胞亚群的变化情况 ,探讨乳腺癌病人机体的免疫状况。方法 应用流式细胞仪测定 33例乳腺癌病人及 2 0例正常健康女性外周血 T细胞亚群 CD3+、CD4 +、 CD8+、 NK细胞的百分比 ,CD4 + / CD8+比率。结果 (1)乳腺癌病人外周血 CD3+、CD4 +、NK显著低于健康女性 (P<0 .0 5 ) ,CD4 + / CD8+比率略低于正常人 ,CD8+高于正常人 ,但两者无显著差异。 (2 ) 、 期乳腺癌 T细胞亚群无明显改变 ,且与正常对照也无明显差异 , 、 期乳腺癌 CD3+ 、 CD4 + 、NK CD4 + / CD8+ 显著低于 、 期 (P<0 .0 5 ) ,CD8+ 百分率显著高于 、 期 (P<0 .0 5 )。 (3)乳腺癌腋淋巴结转移组 (L +) CD3+ 、 CD4 + 、 CD4 + / CD8+ 显著低于腋淋巴结无转移组 (L - ) (P<0 .0 5 ) ,NK细胞百分率 L +组略低于 L -组 ,而 CD8+ 百分率 L +组显著高于 L -组 (P<0 .0 5 )。结论 外周血 T细胞亚群的检测对判断乳腺癌患者的病情、临床分期、预后以及机体的免疫功能的观察有一定意义。早期乳腺癌患者机体免疫功能无明显改变 ,晚期机体免疫功能呈紊乱状态
Objective To analyze the changes of T lymphocyte subsets in peripheral blood of breast cancer patients and to explore the immune status of breast cancer patients. Methods The percentage of CD3 +, CD4 +, CD8 +, NK cells and CD4 + / CD8 + in T lymphocyte subsets of 33 breast cancer patients and 20 normal healthy women were determined by flow cytometry. Results (1) The levels of CD3 +, CD4 + and NK in peripheral blood of patients with breast cancer were significantly lower than those in healthy women (P <0.05). The ratio of CD4 + / CD8 + was slightly lower than that of normal people and CD8 + Significant differences. (2) There was no significant change in the T cell subsets of breast cancer, and there was no significant difference with the normal control. The expression of CD3 +, CD4 +, NK CD4 + / CD8 + in breast cancer was significantly lower than that in the control (P <0.05) ), The percentage of CD8 + was significantly higher than that of the control group (P <0.05). (3) The levels of CD3 +, CD4 +, CD4 + / CD8 + in axillary lymph node metastasis group were significantly lower than those in axillary lymph node metastasis group (P <0.05), the percentage of NK cells in L + Lower than that of L - group, while the percentage of CD8 + L + group was significantly higher than that of L - group (P <0.05). Conclusion The detection of T lymphocyte subsets in peripheral blood is of certain significance in judging the condition, clinical stage, prognosis and immune function of breast cancer patients. Early breast cancer patients with no significant change in immune function, advanced immune function disorders